NCT01551563 Stavanger University Hospital Inflammatory Bowel Disease Trial
| NCT ID | NCT01551563 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helse Stavanger HF |
| Condition | IBD |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2012-04 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2012-04 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims at studying the outcomes of a protocol-based handling of newly diagnosed Inflammatory bowel disease ( IBD ) patients within a defined uptake area in Norway. It is a descriptive study and no hypothesis is predefined. Cytokine studies, QoL and fatigue assessment will be included for hypothesis-generating purposes.
Eligibility Criteria
Inclusion Criteria: * newly diagnosed IBD Exclusion Criteria: * previous IBD with specific treatment within 10 year * inability to consent * inability to adhere to treatment protocol
Contact & Investigator
tore grimstad
✉ tore.bjorn.grimstad@sus.noTore Grimstad, PhD
PRINCIPAL INVESTIGATOR
Helse Stavanger HF
Frequently Asked Questions
Who can join the NCT01551563 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 80 Years, studying IBD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01551563 currently recruiting?
Yes, NCT01551563 is actively recruiting participants. Contact the research team at tore.bjorn.grimstad@sus.no for enrollment information.
Where is the NCT01551563 trial being conducted?
This trial is being conducted at Stavanger, Norway.
Who is sponsoring the NCT01551563 clinical trial?
NCT01551563 is sponsored by Helse Stavanger HF. The principal investigator is Tore Grimstad, PhD at Helse Stavanger HF. The trial plans to enroll 700 participants.